BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 10027349)

  • 1. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
    Faivre J; Tazi MA; El Mrini T; Lejeune C; Benhamiche AM; Dassonville F
    Br J Cancer; 1999 Feb; 79(3-4):680-3. PubMed ID: 10027349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of colorectal cancer screening: results from a population-based case-control evaluation in Saarland, Germany.
    Wahrendorf J; Robra BP; Wiebelt H; Oberhausen R; Weiland M; Dhom G
    Eur J Cancer Prev; 1993 May; 2(3):221-7. PubMed ID: 8490540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan.
    Lee KJ; Inoue M; Otani T; Iwasaki M; Sasazuki S; Tsugane S;
    Cancer Detect Prev; 2007; 31(1):3-11. PubMed ID: 17289293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
    Malila N; Hakama M; Pukkala E
    Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
    Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
    Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control study to evaluate efficacy of screening for faecal occult blood.
    Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH
    J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mass screening for colorectal cancer].
    Faivre J; Tazi MA; Launoy G
    Rev Epidemiol Sante Publique; 1996; 44 Suppl 1():S7-14. PubMed ID: 8935859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
    Chew MH; Suzanah N; Ho KS; Lim JF; Ooi BS; Tang CL; Eu KW
    Singapore Med J; 2009 Apr; 50(4):348-53. PubMed ID: 19421676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer.
    N Z Med J; 1999 Jan; 112(1080):4-6. PubMed ID: 10073156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidemiology and screening of colorectal cancer].
    Dancourt V; Faivre J
    Rev Prat; 2004 Jan; 54(2):135-42. PubMed ID: 15086055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.
    Mandel JS; Bond JH; Church TR; Snover DC; Bradley GM; Schuman LM; Ederer F
    N Engl J Med; 1993 May; 328(19):1365-71. PubMed ID: 8474513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer mortality in two areas of Tuscany with different screening exposures.
    Costantini AS; Martini A; Puliti D; Ciatto S; Castiglione G; Grazzini G; Zappa M
    J Natl Cancer Inst; 2008 Dec; 100(24):1818-21. PubMed ID: 19066268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of repeated screening using the fecal occult blood test and its impact on reducing false-negative cancer cases.
    Nishida H; Urano S
    Eur J Cancer Prev; 2011 May; 20(3):184-9. PubMed ID: 21301345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
    Malila N; Oivanen T; Hakama M
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.
    Selby JV; Friedman GD; Quesenberry CP; Weiss NS
    N Engl J Med; 1992 Mar; 326(10):653-7. PubMed ID: 1736103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for colorectal cancer.
    Mandel JS
    Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.